: As widely acknowledged, 40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E). The identification of the RAS-RAF-MEK-ERK (MAP kinase) signalling pathway and its targeting has represented a valuable milestone for the advanced and, more recently, for the completely resected stage III and IV melanoma therapy management. However, despite progress in BRAF-mutant melanoma treatment, the two different approaches approved so far for metastatic disease, immunotherapy and BRAF+MEK inhibitors, allow a 5-year survival of no more than 60%, and most patients relapse during treatment due to acquired mechanisms of resistance. Deep insight into BRAF gene biology is fundamental to describe the acquired resistance mechanisms (primary and secondary) and to understand the molecular pathways that are now being investigated in preclinical and clinical studies with the aim of improving outcomes in BRAF-mutant patients.

BRAF Gene and Melanoma: Back to the Future / Ottaviano, Margaret; Giunta, Emilio Francesco; Tortora, Marianna; Curvietto, Marcello; Attademo, Laura; Bosso, Davide; Cardalesi, Cinzia; Rosanova, Mario; De Placido, Pietro; Pietroluongo, Erica; Riccio, Vittorio; Mucci, Brigitta; Parola, Sara; Vitale, Maria Grazia; Palmieri, Giovannella; Bruno, Daniele; Simeone, Ester; On Behalf Of Scito Youth, Null. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 22:7(2021), p. 3474. [10.3390/ijms22073474]

BRAF Gene and Melanoma: Back to the Future

Ottaviano, Margaret;Attademo, Laura;Bosso, Davide;Cardalesi, Cinzia;Rosanova, Mario;De Placido, Pietro;Pietroluongo, Erica;Riccio, Vittorio;Mucci, Brigitta;Parola, Sara;Vitale, Maria Grazia;Palmieri, Giovannella;Daniele, Bruno;
2021

Abstract

: As widely acknowledged, 40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E). The identification of the RAS-RAF-MEK-ERK (MAP kinase) signalling pathway and its targeting has represented a valuable milestone for the advanced and, more recently, for the completely resected stage III and IV melanoma therapy management. However, despite progress in BRAF-mutant melanoma treatment, the two different approaches approved so far for metastatic disease, immunotherapy and BRAF+MEK inhibitors, allow a 5-year survival of no more than 60%, and most patients relapse during treatment due to acquired mechanisms of resistance. Deep insight into BRAF gene biology is fundamental to describe the acquired resistance mechanisms (primary and secondary) and to understand the molecular pathways that are now being investigated in preclinical and clinical studies with the aim of improving outcomes in BRAF-mutant patients.
2021
BRAF Gene and Melanoma: Back to the Future / Ottaviano, Margaret; Giunta, Emilio Francesco; Tortora, Marianna; Curvietto, Marcello; Attademo, Laura; Bosso, Davide; Cardalesi, Cinzia; Rosanova, Mario; De Placido, Pietro; Pietroluongo, Erica; Riccio, Vittorio; Mucci, Brigitta; Parola, Sara; Vitale, Maria Grazia; Palmieri, Giovannella; Bruno, Daniele; Simeone, Ester; On Behalf Of Scito Youth, Null. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 22:7(2021), p. 3474. [10.3390/ijms22073474]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/917661
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact